GFH009 to be Evaluated Against Pediatric Solid Tumors and Leukemia Models at Eight Participating Research Institutions NEW YORK, Dec. 06, 2022 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results